Expression of hypoxia-inducible factor-1α in liver tumors after transcatheter arterial embolization in an animal model

Abstract

To examine the effect of transcatheter arterial embolization (TAE) of liver tumors on hypoxia-inducible factor-1α (HIF-1α) expression in the residual viable tumor, a total of 30 New Zealand White rabbits implanted with VX2 liver tumor were divided into 2 groups. TAE-treated group animals (n=15) were subjected to TAE with 150–250 μm polyvinyl alcohol particles. Control group animals (n=15) underwent sham embolization with distilled water. Six hours, 3 days or 7 days after TAE, the animals were sacrificed, and samples of tumor and adjacent normal liver tissue were harvested. Expression of HIF-1α protein was examined immunohistochemically. Real-time PCR was performed to examine the HIF-1α mRNA levels. Our results showed that HIF-1α protein was expressed in the VX2 tumors but not in the adjacent normal liver tissue. The HIF-1α-positive tumor cells were located predominantly at the periphery of necrotic tumor regions. The mean levels of HIF-1α protein were significantly higher in TAE-treated tumors than those in control tumors (P=0.002). Among the three sacrificing time points, the difference in increase in HIF-1α protein was significant between the two groups at the sacrificing time point of 6 h and 3 days after TAE (P=0.020, P=0.031, respectively), whereas no significant increase was noted 7 days after TAE (P=0.502). In contrast, although HIF-1α mRNA was expressed in TAE-treated and control VX2 tumors, there existed no significant difference in the HIF-1α mRNA level between the two groups (P=0.372). It is concluded that TAE of liver tumors increases the expression of HIF-1α at protein level in the residual viable tumor, which could be attributed to hypoxia generated by the procedure.

Keywords

embolization / hypoxia-inducible factor-1 / liver neoplasms

References

[1] BrownD.B., GouldJ.E., GervaisD.A., et al.. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol, 2007, 18(12): 1469-1478

[2] BreedisC., YoungG.. The blood supply of neoplasms in the liver. Am J Pathol, 1954, 30(5): 969-977

[3] BrownD.B., CardellaJ.F., SacksD., et al.. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol, 2006, 17(2Pt1): 225-232

[4] GuptaS., KobayashiS., PhongkitkarunS., et al.. Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol, 2006, 41(6): 516-521

[5] LeeJ.K., ChungY.H., SongB.C., et al.. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol, 2002, 17(1): 52-58

[6] LiouT.C., ShihS.C., KaoC.R., et al.. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol, 1995, 23(5): 563-568

[7] WangB., XuH., GaoZ.Q., et al.. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol, 2008, 49(5): 523-529

[8] SongB.C., ChungY.H., KimJ.A., et al.. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer, 2001, 91(12): 2386-2393

[9] HuangJ., HeX., LinX., et al.. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma. Chin Med J (Engl), 2000, 113(5): 446-448

[10] KimY.B., ParkY.N., ParkC.. Increased proliferation activities of vascular endothelial cells and tumour cells in residual hepatocellular carcinoma following transcatheter arterial embolization. Histopathology, 2001, 38(2): 160-166

[11] KobayashiN., IshiiM., UenoY., et al.. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver, 1999, 19(1): 25-31

[12] SemenzaG.L., WangG.L.. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992, 12(12): 5447-5454

[13] SemenzaG.L.. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003, 3(10): 721-732

[14] RamseyD.E., KernagisL.Y., SoulenM.C., et al.. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol, 2002, 13(9Pt2): S211-221

[15] ChenJ.H., LinY.C., HuangY.S., et al.. Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods. Lab Anim, 2004, 38(1): 79-84

[16] ZhongH., De MarzoA.M., LaughnerE., et al.. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res, 1999, 59(22): 5830-5835

[17] SchmittgenT.D., ZakrajsekB.A., MillsA.G., et al.. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem, 2000, 285(2): 194-204

[18] SemenzaG.L.. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003, 3(10): 721-732

[19] YasudaS., AriiS., MoriA., et al.. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol, 2004, 40(1): 117-123

[20] YangZ.F., PoonR.T., ToJ., et al.. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res, 2004, 64(15): 5496-5503

[21] WangY., FengG.S., QianJ., et al.. Effect of hepatic arterial blockage on HIF-1α and VEGF expression of transplanted hepatoma in rats. J Clin Radiol (Chinese), 2006, 25(8): 775-777

[22] RheeT.K., YoungJ.Y., LarsonA.C., et al.. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol, 2007, 18(5): 639-645

[23] VirmaniS., RheeT.K., RyuR.K., et al.. Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Interv Radiol, 2008, 19(10): 1483-1489

[24] SuC., ZhangH.Z., LiW.H., et al.. Culture in vitro and related biological characteristics of rabbit VX2 carcinoma cells. J Fourth Mil Med Univ (Chinese), 2006, 27(9): 844-847

[25] SerganovaI., DoubrovinM., ViderJ., et al.. Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res, 2004, 64(17): 6101-6108

[26] LiuJ., QuR., OguraM., et al.. Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (Tokyo), 2005, 46(1): 93-102

[27] KaurB., KhwajaF.W., SeversonE.A., et al.. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol, 2005, 7(2): 134-153

[28] HelmlingerG., YuanF., DellianM., et al.. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med, 1997, 3(2): 177-182

[29] TalksK.L., TurleyH., GatterK.C., et al.. The expression and distribution of the hypoxia-inducible factors HIF-1αlpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol, 2000, 157(2): 411-421

[30] KarthJ., FerrerF.A., PerlmanE., et al.. Coexpression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in Wilms’ tumor. J Pediatr Surg, 2000, 35(12): 1749-1753

[31] GaoW., GaoY., ZhangG., et al.. Hypoxia-induced expression of HIF-1αlpha and its target genes in umbilical venous endothelial cells of Tibetans and immigrant Han. Comp Biochem Physiol C Toxicol Pharmacol, 2005, 141(1): 93-100